GLP-1 Agonists

Expert Positions

Andrew Huberman

Favorable — Covers Science Extensively

Peter Attia

Strongly Favorable with Caveats

Rhonda Patrick

Limited Direct Coverage

Bryan Johnson

Limited Direct Coverage

Mark Hyman

Strongly Opposes Widespread Use

The Verdict

This is one of the most polarizing topics across our expert panel. Attia and Huberman see GLP-1 agonists as powerful tools when combined with exercise and high protein intake, while Hyman strongly opposes their widespread use, arguing they mask root causes and create pharmaceutical dependency. This is a prescription medication, not a supplement — use requires physician oversight.